These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37074724)

  • 1. How Do We Credit the Evidence Generated From Subgroup Analyses in Randomized Clinical Trials?
    Cheng Y; He N; Yan Y
    JAMA Cardiol; 2023 Jun; 8(6):623. PubMed ID: 37074724
    [No Abstract]   [Full Text] [Related]  

  • 2. How Do We Credit the Evidence Generated From Subgroup Analyses in Randomized Clinical Trials?-Reply.
    Hlatky MA; Stone NJ; Manson JE
    JAMA Cardiol; 2023 Jun; 8(6):623. PubMed ID: 37074696
    [No Abstract]   [Full Text] [Related]  

  • 3. Misuse of baseline comparison tests and subgroup analyses in surgical trials.
    Bhandari M; Devereaux PJ; Li P; Mah D; Lim K; Schünemann HJ; Tornetta P
    Clin Orthop Relat Res; 2006 Jun; 447():247-51. PubMed ID: 16672904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses.
    Hennekens CH; Demets D
    JAMA; 2009 Dec; 302(21):2361-2. PubMed ID: 19952322
    [No Abstract]   [Full Text] [Related]  

  • 5. Justification and reporting of subgroup analyses were lacking or inadequate in randomized controlled trials.
    Fan J; Song F; Bachmann MO
    J Clin Epidemiol; 2019 Apr; 108():17-25. PubMed ID: 30557676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup analyses in randomized clinical trials: statistical and regulatory issues.
    Grouin JM; Coste M; Lewis J
    J Biopharm Stat; 2005; 15(5):869-82. PubMed ID: 16078390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials.
    Sun X; Briel M; Busse JW; Akl EA; You JJ; Mejza F; Bala M; Diaz-Granados N; Bassler D; Mertz D; Srinathan SK; Vandvik PO; Malaga G; Alshurafa M; Dahm P; Alonso-Coello P; Heels-Ansdell DM; Bhatnagar N; Johnston BC; Wang L; Walter SD; Altman DG; Guyatt GH
    Trials; 2009 Nov; 10():101. PubMed ID: 19900273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup analysis in randomized controlled trials appeared to be dependent on whether relative or absolute effect measures were used.
    Venekamp RP; Rovers MM; Hoes AW; Knol MJ
    J Clin Epidemiol; 2014 Apr; 67(4):410-5. PubMed ID: 24508145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings of the University of Pennsylvania 14th annual conference on statistical issues in clinical trials: Subgroup analysis in randomized clinical trials-Challenges and opportunities.
    Ellenberg SS; Ellenberg JH
    Clin Trials; 2023 Aug; 20(4):325-327. PubMed ID: 37203142
    [No Abstract]   [Full Text] [Related]  

  • 10. Subgroup analyses in nephrology clinical trials.
    Fishbane S; Shah HH; Kataria A; Shirazian S; Agarwal R
    Clin J Am Soc Nephrol; 2012 Nov; 7(11):1872-6. PubMed ID: 22837274
    [No Abstract]   [Full Text] [Related]  

  • 11. [Roaming through methodology. IX. The interpretation of subgroup analyses].
    van der Windt DA; van Poppel MN
    Ned Tijdschr Geneeskd; 1998 Oct; 142(41):2245-7. PubMed ID: 9864501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of subgroup analyses.
    Eisner MD
    N Engl J Med; 2006 Jul; 355(2):211; author reply 211-2. PubMed ID: 16837688
    [No Abstract]   [Full Text] [Related]  

  • 13. Subgroup analyses.
    Oxman AD
    BMJ; 2012 Mar; 344():e2022. PubMed ID: 22422834
    [No Abstract]   [Full Text] [Related]  

  • 14. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and solutions to pre- and post-randomization subgroup analyses.
    Desai M; Pieper KS; Mahaffey K
    Curr Cardiol Rep; 2014; 16(10):531. PubMed ID: 25135344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical issues in interpreting clinical trials.
    DeMets DL
    J Intern Med; 2004 May; 255(5):529-37. PubMed ID: 15078496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup analysis and other (mis)uses of baseline data in clinical trials.
    Assmann SF; Pocock SJ; Enos LE; Kasten LE
    Lancet; 2000 Mar; 355(9209):1064-9. PubMed ID: 10744093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup analyses: primary and secondary.
    Detsky AS; Naglie IG
    ACP J Club; 1995; 122(3):A12-4. PubMed ID: 7728420
    [No Abstract]   [Full Text] [Related]  

  • 19. Rudiments of subgroup analyses.
    Moyé LA
    Prog Cardiovasc Dis; 2012; 54(4):338-42. PubMed ID: 22226001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.
    Brookes ST; Whitely E; Egger M; Smith GD; Mulheran PA; Peters TJ
    J Clin Epidemiol; 2004 Mar; 57(3):229-36. PubMed ID: 15066682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.